𝔖 Bobbio Scriptorium

✦ LIBER ✦

409 AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies — a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study

✍ Scribed by M. Mita; E. Rowinsky; A. Mita; S. Syed; Q. Chu; M. Goldston; H. Knowles; V. Rivera; C. Bedrosian; A. Tolcher

Book ID: 118621591
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 149 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(04)80416-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

390 A phase I trial of weekly AP23573, a

390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis

✍ A.A. Desai; L. Janisch; L. Berk; H.L. Knowles; V.M. Rivera; H.L. Kindler; W.M. S 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 142 KB

A phase I pharmacokinetic (PK) and seria

A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 256 KB